By browsing our site you agree to our use of cookies. You will only see this message once. Find out more
We regret to inform you that we have ceased publication of current announcements.
Unitedkingdom-tenders.co.uk domain is for sale. Please contact us.

The supply of rituximab (MabThera) 1400mg/11.7ml subcutaneous injection to NHS Scotland.

Contract award notice

Results of the procurement procedure

Supplies

Directive 2014/24/EU

Section I: Contracting authority

I.1)Name and addresses
The Common Services Agency (more commonly known as NHS National Services Scotland) (‘NSS’)
Gyle Square (NSS Head Office), 1 South Gyle Crescent
Edinburgh
EH12 9EB
United Kingdom
Telephone: +44 1698794410
E-mail:
NUTS code: UKM

Internet address(es):

Main address: http://www.nhsscotlandprocurement.scot.nhs.uk/

Address of the buyer profile: http://www.publiccontractsscotland.gov.uk/search/Search_AuthProfile.aspx?ID=AA11883

I.2)Joint procurement
The contract is awarded by a central purchasing body
I.4)Type of the contracting authority
Body governed by public law
I.5)Main activity
Health

Section II: Object

II.1)Scope of the procurement
II.1.1)Title:

Rituximab (MabThera®) 1400mg/11.7ml Subcutaneous Injection.

Reference number: NP93417 (a)
II.1.2)Main CPV code
33690000
II.1.3)Type of contract
Supplies
II.1.4)Short description:

The supply of rituximab (MabThera) 1400mg/11.7ml subcutaneous injection to NHS Scotland.

II.1.6)Information about lots
This contract is divided into lots: no
II.1.7)Total value of the procurement (excluding VAT)
Value excluding VAT: 7 057 330.00 GBP
II.2)Description
II.2.1)Title:
II.2.2)Additional CPV code(s)
II.2.3)Place of performance
NUTS code: UKM
Main site or place of performance:

All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014.

II.2.4)Description of the procurement:

The supply of rituximab (MabThera®) 1 400 mg/11.7ml subcutaneous injection to NHS Scotland.

II.2.5)Award criteria
Price
II.2.11)Information about options
Options: no
II.2.13)Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds: no
II.2.14)Additional information

Section IV: Procedure

IV.1)Description
IV.1.1)Type of procedure
Award of a contract without prior publication of a call for competition in the Official Journal of the European Union in the cases listed below
  • The works, supplies or services can be provided only by a particular economic operator for the following reason:
    • protection of exclusive rights, including intellectual property rights
Explanation:

The medicine awarded to this framework agreement is, and will remain to be, protected by patent for the duration of the framework agreement.

IV.1.3)Information about a framework agreement or a dynamic purchasing system
The procurement involves the establishment of a framework agreement
IV.1.6)Information about electronic auction
IV.1.8)Information about the Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement: yes
IV.2)Administrative information
IV.2.1)Previous publication concerning this procedure
Notice number in the OJ S: 2017/S 131-267908
IV.2.8)Information about termination of dynamic purchasing system
IV.2.9)Information about termination of call for competition in the form of a prior information notice

Section V: Award of contract

Contract No: NP93417
A contract/lot is awarded: yes
V.2)Award of contract
V.2.1)Date of conclusion of the contract:
24/07/2017
V.2.2)Information about tenders
Number of tenders received: 1
The contract has been awarded to a group of economic operators: no
V.2.3)Name and address of the contractor
Roche Products Ltd
6 Falcon Way, Shire Park
Welwyn Garden City
AL7 1TW
United Kingdom
NUTS code: UK
The contractor is an SME: no
V.2.4)Information on value of the contract/lot (excluding VAT)
Total value of the contract/lot: 7 057 330.00 GBP
V.2.5)Information about subcontracting

Section VI: Complementary information

VI.3)Additional information:

The total value in Section II.1.7 and V.2.4 refers to the twenty three (23) months initial duration and the full twelve (12) month extension option.

(SC Ref:506381).

VI.4)Procedures for review
VI.4.1)Review body
The Common Services Agency (more commonly known as NHS National Services Scotland) (‘NSS’)
Gyle Square (NSS Head Office), 1 South Gyle Crescent
Edinburgh
EH12 9EB
United Kingdom
Telephone: +44 1698794571

Internet address:http://www.nhsscotlandprocurement.scot.nhs.uk/

VI.4.2)Body responsible for mediation procedures
VI.4.3)Review procedure
Precise information on deadline(s) for review procedures:

The bringing of court proceedings against the Authority after the framework agreement has been entered into will not affect the framework agreement unless grounds for the imposition of special penalties under the Public Contracts (Scotland) Regulations 2015 can be established. Otherwise the remedies that may be awarded by the courts where the framework agreement has been entered into are limited to the award of damages.

VI.4.4)Service from which information about the review procedure may be obtained
VI.5)Date of dispatch of this notice:
31/07/2017